Attaya Suvannasankha
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (15)
Year:
2026
Year:
2026
Year:
2026
The emergence of bispecific antibodies for multiple myeloma presents a critical unanswered question for solid organ transplant recipients: Can these T-cell dependent therapies overcome concurrent immunosuppression without triggering graft rejection? While teclistamab and similar agents demonstrate remarkable efficacy in immunocompetent patients, their mechanism demands functional T-cells—precisely what calcineurin inhibitors and antimetabolites suppress in transplant recipients. This creates a perilous therapeutic trilemma: (1) Maintaining standard immunosuppression risks blunting bispecific efficacy, (2) reducing immunosuppression may precipitate graft rejection, while (3) both strategies compound already elevated infection risks from dual immunosuppressive effects. Our experience treating two renal transplant recipients with teclistamab reveals these tensions in practice—one patient achieved sustained response without rejection, while another faced infectious complications preceding disease progression. These cases highlight three urgent research priorities: prospective studies to define (a) minimum effective immunosuppression levels during bispecific therapy, (b) biomarkers predicting graft rejection risk, and (c) optimal infection prophylaxis strategies. Until such data exists, clinicians navigate this high-stakes balancing act without evidence, forced to weigh theoretical risks of allograft loss against known mortality from progressive myeloma.
Year:
2026
Modeling progressive disease based on immune cell composition. A, Kaplan–Meier curve of high risk ( n = 17) and low risk ( n = 18) of progression-defined groups. Shading represents 95% confidence intervals. B, Model prediction of cell interactions positively associated with progression. C, Model prediction of cell interactions negatively associated with progression. Those in red involve T-cell subsets. D, Correlation between the stromal::CD8 T exhausted cell proportions and progression. E, Kaplan–Meier curve of high and low risk of progression groups from the validation cohort. F, Proportion of model HR for complete response (CR; n = 8), very good PR (VGPR; n = 9), or PR ( n = 3; P = 0.045). G, Proportion of model HR for patients with sustained MRD negativity ( n = 10) and without sustained MRD negativity ( n = 10; P = 0.002). The bottom and top edges of the box represent the 25th and 75th quartiles, respectively, and the middle line denotes median. The whiskers extend to 1.5 times the interquartile range of 25th and 75th quartiles. [Note: the plots do not include two outlier points (−0.113 and −0.031) from MRD-sustained and CR patients because their hazard scores were so low that it affected the plot visualization.] PCC. Pearson correlation coefficient; T eff, effector T cell; T exh, exhausted T cell; T mem, memory T cell; T reg, regulatory T cell; T tox, toxic T cell.
Year:
2025
A key treatment for patients with multiple myeloma is high-dose melphalan followed by autologous stem cell transplant (ASCT). It can provide a deep response with long-term remission. However, some patients progress quickly, and it is not clear why. In this study, we performed single-cell RNA and T-cell receptor sequencing of the immune microenvironment of 40 patients before and after ASCT to determine if differences in the immune composition could define those who would progress. Clear differences in cell populations were identified in progressors, including increased T-cell infiltration, decreased T-cell receptor diversity, and decreased frequency of monocytes and CD56 bright NK cells. We identified cell interactions that predicted progression, including increased frequency of CD8 + exhausted T cells and stromal cells and decreased frequency of CD56 bright NK cells and plasmacytoid dendritic cells. We propose and validate a model of progression that can also be determined by flow cytometry. Together, these data highlight the importance of the immune microenvironment in understanding responses to ASCT.
Year:
2025
B cell to T cell/NK cell ratio (B:T/NK) is associated with progression after ASCT. A, MRD flow panel percentages of B and T+NK cells after ASCT. B, Correlation of flow panel and single-cell percentages. C, The ratio of B/T+NK cells is associated with progression in both flow panel and single-cell datasets. NP, nonprogressor, P, progressor.
Year:
2025
Time to progression correlates with decreased T-cell frequencies and increased monocyte frequencies. A, Identification and mapping of cell-type subclusters. B, Optimal forest plot of cell types associated with outcomes in univariate analysis. C, High CD4 + T memory cells are associated with early progression after ASCT. D, High CD8 + exhausted T cells are associated with early progression after ASCT. E, Significant differences in expanded clonotype T-cell proportions between nonprogressors (NP) and progressors (P). CI, confidence interval; T eff, effector T cell; T exh, exhausted T cell; T mem, memory T cell; T reg, regulatory T cell.
Year:
2025
NK cell CD56 bright /CD56 dim ratio is associated with progression. A, UMAP of NK cells identifying three populations. B, NK cell populations are defined by the expression of CD56 ( NCAM1 ) and NKG7 . C, Expression of CD56 ( NCAM1 ) in CD56 bright and CD56 dim cells. D, NK cell populations do not differ between progression states except for CD56 dim NK cells after ASCT. E, The ratio of CD56 bright to CD56 dim cells is significantly different after ASCT. NP, nonprogressors; P, progressors.
Year:
2025
Single-cell transcriptomic profiling of the bone marrow microenvironment before and after ASCT identifies cell types associated with progression. A, Overview of the study. B, PFS Kaplan–Meier plot for study patients. C, Patient-integrated annotated cell clusters. D, Mean proportions of cell types in progressor (P) and nonprogressor (NP) patients.
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Collaborators (14)
Mansi Shah
Rutgers Cancer Institute of New Jersey
Ola Landgren
Professor of Medicine
Sylvester Comprehensive Cancer Center, University of Miami
Brian Walker
Professor
University of Miami
Enze Liu
Research track Assistant Professor
University of Miami Health System
Travis S Johnson
Assistant Research Professor
Indiana University School of Medicine
Habib Hamidi
Distinguished Scientist Translational Bioinformatics
Genentech Inc
Sherif Farag
Professor of Medicine
Indiana University School of Medicine
Sagar Lonial
-
Jesus F. San Miguel
-
Ajay K. Nooka
Professor
Emory University
Ashraf Badros
Professor of Medicine/Director of Multiple Myeloma service
University of Maryland
Bruno David Lourenço Paiva
Clinica Universidad de Navarra
rachid baz
H Lee Moffitt Cancer Center and Research Institute
Adam Cohen
Associate Professor, Clinician-Educator
University of Pennsylvania
Make your next move.
Prepare your application
Review drafts before you send them.